Form 4: ANI Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Thomas Andrew Rowland, SVP at ANI Pharmaceuticals, disposed of 627 shares to cover tax obligations related to vesting restricted stock.
Summary
- On February 28, 2025, Thomas Andrew Rowland, SVP, HEAD ESTABLISHED BRANDS of ANI Pharmaceuticals, disposed of 627 shares of common stock.
- The shares were sold at a price of $61.89 per share.
- This transaction was to cover tax obligations related to the vesting of 2,171 shares of restricted stock.
- Following the transaction, Rowland directly owns 45,465 shares of ANI Pharmaceuticals.
- The transaction was exempt under Rule 16(b)-3.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (selling shares to cover tax obligations). It doesn't indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, and are required by the SEC to ensure transparency of trading by corporate insiders.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale of shares by an executive to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of transaction: Thomas Andrew Rowland disposed of 627 shares. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.